GlassScriptPhysician profile
Hafeez A Syed
NPI 1952403701
$2,813.74
in general payments reported to CMS, 2019-2025
20 companies · $160 in 2025
The $160 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $540 · 2020: $322 · 2021: $589 · 2022: $486 · 2023: $512 · 2024: $206 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $877.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $728.64 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $303.80 | 2020-2023 | Xarelto |
| Alnylam Pharmaceuticals INC. | $250.45 | 2022-2025 | Amvuttra, Onpattro |
| Astrazeneca Pharmaceuticals LP | $233.34 | 2019-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $224.23 | 2021-2023 | Verquvo |
| Amgen INC. | $204.36 | 2019-2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.61 | 2021-2024 | Jardiance |
| Esperion Therapeutics, INC. | $160.18 | 2020-2024 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $134.74 | 2019-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $123.04 | 2021-2025 | Wegovy, Ozempic |
| Sanofi-Aventis U.S. LLC | $66.38 | 2019 | |
| Boston Scientific Corporation | $56.81 | 2023 | Watchman Access System |
| Regeneron Healthcare Solutions, INC. | $30.32 | 2019 | |
| Atricure, INC. | $22.71 | 2023 | |
| Glaxosmithkline, LLC. | $20.36 | 2025 | Arexvy, Shingrix |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $19.70 | 2019 | |
| Scpharmaceuticals INC. | $18.10 | 2023 | |
| Abbott Laboratories | $16.77 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.66 | 2021 | |
| Lundbeck LLC | $12.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hafeez Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.